Dear Doctor - Participate in the Survey on metoprolol " A new survey has found that the vast majority of people who take the blood pressure medication metoprolol are satisfied with the results. The survey, which was conducted by Consumer Reports, polled more than 1,000 people who were taking metoprolol and found that 92% were satisfied with the drug.Metoprolol is a beta-blocker that is typically used to treat hypertension, or high blood pressure. It works by blocking the action of certain hormones in the body that can raise blood pressure. Beta-blockers are some of the most commonly prescribed medications for hypertension, and metoprolol is one of the most popular choices.The Consumer Reports survey found that people who took metoprolol felt it was effective in lowering their blood pressure and reducing their risk of heart attack or stroke. They also reported few side effects from the drug. The most common side effect reported was fatigue, but only 10% of those surveyed said it was a problem for them.Overall, the survey found that metoprolol is an effective and well-tolerated medication for hypertension. If you are taking metoprolol or considering starting on this medication, be sure to speak to your doctor about your specific situation to see if it is right for you. Participate in Surveys "
1.
Colon cancer and exercise: Can physical activity reprogram genes?
2.
For relapsed or resistant DLBCL, odronextamab produced positive results.
3.
Improved end-of-life conversations for cancer patients are identified by a new study.
4.
Another KRAS Inhibitor Scores an Early Win in Advanced Non-Small Cell Lung Cancer
5.
Xerostomia in Head and Neck Cancer Patients Can Be Predicted by Mid-Treatment PET/CT Scans.
1.
Treating Methemoglobinemia: What You Need to Know Now!
2.
Is AI The New Radiologist For Breast MRI?
3.
Advancements in Squamous Cell Carcinoma Treatment: Decoding Survival Strategies and Molecular Pathways to Improve Cure Rates
4.
Unlocking the Potential of Pirtobrutinib: A New Frontier in Cancer Treatment
5.
Unleashing the Oncolytic Arsenal: Talimogene Laherparepvec Monotherapy – A Targeted Cancer Immunotherapy Treatment
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
2.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
4.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
5.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation